SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis

References

• Dai Y, Faller DV. Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics 2008; 3:53 - 65; PMID: 21566744
   PubMedGoogle Scholar
• Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol 2011; 206:13 - 37; http://dx.doi.org/10.1007/978-3-642-21631-2_2; PMID: 21879444
   PubMedGoogle Scholar
• Johnsson AE, Wright AP. The role of specific HAT-HDAC interactions in transcriptional elongation. Cell Cycle 2010; 9:467 - 71; http://dx.doi.org/10.4161/cc.9.3.10543; PMID: 20081370
   PubMed Web of Science ®Google Scholar
• Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007; 13:23 - 9; http://dx.doi.org/10.1097/PPO.0b013e31803c72ba; PMID: 17464243
   PubMed Web of Science ®Google Scholar
• Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 2007; 26:6697 - 714; http://dx.doi.org/10.1038/sj.onc.1210755; PMID: 17934479
   PubMed Web of Science ®Google Scholar
• Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011; 2011:371832; http://dx.doi.org/10.1155/2011/371832; PMID: 21151613
   PubMed Web of Science ®Google Scholar
• Schneider G, Krämer OH, Schmid RM, Saur D. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J Gastrointest Cancer 2011; 42:85 - 92; http://dx.doi.org/10.1007/s12029-011-9257-1; PMID: 21271301
   PubMedGoogle Scholar
• Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31 - 9; http://dx.doi.org/10.1182/blood-2006-06-025999; PMID: 16960145
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16:1111 - 20; http://dx.doi.org/10.1517/13543784.16.7.1111; PMID: 17594194
   PubMed Web of Science ®Google Scholar
• Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2009; 9:412 - 6; http://dx.doi.org/10.3816/CLM.2009.n.082; PMID: 19951879
   PubMedGoogle Scholar
• Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 2012; 4:471 - 86; http://dx.doi.org/10.4155/fmc.12.6; PMID: 22416775
   PubMed Web of Science ®Google Scholar
• Sato A. Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. Onco Targets Ther 2012; 5:67 - 76; http://dx.doi.org/10.2147/OTT.S23874; PMID: 22573938
   PubMed Web of Science ®Google Scholar
• Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125:1045 - 52; http://dx.doi.org/10.1111/j.0022-202X.2005.23925.x; PMID: 16297208
   PubMed Web of Science ®Google Scholar
• Frye R, Myers M, Axelrod KC, Ness EA, Piekarz RL, Bates SE, Booher S. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs 2012; 16:195 - 204; http://dx.doi.org/10.1188/12.CJON.195-204; PMID: 22459529
   PubMed Web of Science ®Google Scholar
• Haigentz M Jr., Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 2012; 48:1281 - 8; http://dx.doi.org/10.1016/j.oraloncology.2012.05.024; PMID: 22748449
   PubMed Web of Science ®Google Scholar
• Kim M, Thompson LA, Wenger SD, O’Bryant CL. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. Ann Pharmacother 2012; 46:1340 - 8; http://dx.doi.org/10.1345/aph.1R036; PMID: 22968522
   PubMed Web of Science ®Google Scholar
• Prince HM, Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin Cancer Res 2012; 18:3509 - 15; http://dx.doi.org/10.1158/1078-0432.CCR-11-3144; PMID: 22535155
   PubMed Web of Science ®Google Scholar
• Stutz N, Johnson RD, Wood GS. The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis. J Am Acad Dermatol 2012; 67:e1 - 10; PMID: 22884443
   PubMedGoogle Scholar
• Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol 2001; 145:928 - 37; http://dx.doi.org/10.1046/j.1365-2133.2001.04523.x; PMID: 11899146
   PubMed Web of Science ®Google Scholar
• Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 2005; 124:741 - 50; http://dx.doi.org/10.1111/j.0022-202X.2005.23657.x; PMID: 15816832
   PubMed Web of Science ®Google Scholar
• Vermeer MH, van Doorn R, Dukers D, Bekkenk MW, Meijer CJ, Willemze R. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19:4322 - 9; PMID: 11731515
   PubMed Web of Science ®Google Scholar
• Contassot E, French LE. Targeting apoptosis defects in cutaneous T-cell lymphoma. J Invest Dermatol 2009; 129:1059 - 61; http://dx.doi.org/10.1038/jid.2009.14; PMID: 19369931
   PubMed Web of Science ®Google Scholar
• Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011; 147:443 - 9; http://dx.doi.org/10.1001/archdermatol.2010.376; PMID: 21173302
   PubMed Web of Science ®Google Scholar
• Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129:1165 - 73; http://dx.doi.org/10.1038/jid.2008.309; PMID: 18923451
   PubMed Web of Science ®Google Scholar
• Carafa V, Nebbioso A, Altucci L. Sirtuins and disease: the road ahead. Front Pharmacol 2012; 3:4; http://dx.doi.org/10.3389/fphar.2012.00004; PMID: 22319497
   PubMed Web of Science ®Google Scholar
• Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012; 13:225 - 38; PMID: 22395773
   PubMed Web of Science ®Google Scholar
• Zschoernig B, Mahlknecht U. SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun 2008; 376:251 - 5; http://dx.doi.org/10.1016/j.bbrc.2008.08.137; PMID: 18774777
   PubMed Web of Science ®Google Scholar
• Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26:5489 - 504; http://dx.doi.org/10.1038/sj.onc.1210616; PMID: 17694089
   PubMed Web of Science ®Google Scholar
• Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, Dai Y. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci 2010; 6:599 - 612; http://dx.doi.org/10.7150/ijbs.6.599; PMID: 20941378
   PubMed Web of Science ®Google Scholar
• Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011; 2:648 - 62; http://dx.doi.org/10.1177/1947601911417862; PMID: 21941620
   PubMedGoogle Scholar
• Deng CX. SIRT1, is it a tumor promoter or tumor suppressor?. Int J Biol Sci 2009; 5:147 - 52; http://dx.doi.org/10.7150/ijbs.5.147; PMID: 19173036
   PubMed Web of Science ®Google Scholar
• Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454 - 63; http://dx.doi.org/10.1016/j.ccr.2008.03.004; PMID: 18455128
   PubMed Web of Science ®Google Scholar
• Olmos Y, Brosens JJ, Lam EW. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist Updat 2011; 14:35 - 44; http://dx.doi.org/10.1016/j.drup.2010.12.001; PMID: 21195657
   PubMed Web of Science ®Google Scholar
• Lamprecht B, Kreher S, Möbs M, Sterry W, Dörken B, Janz M, Assaf C, Mathas S. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome. Br J Dermatol 2012; 167:240 - 6; http://dx.doi.org/10.1111/j.1365-2133.2012.10918.x; PMID: 22384858
   PubMed Web of Science ®Google Scholar
• Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990; 10:5502 - 9; PMID: 2144611
   PubMed Web of Science ®Google Scholar
• Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008; 32:1523 - 31; http://dx.doi.org/10.1097/PAS.0b013e31816b6478; PMID: 18724249
   PubMed Web of Science ®Google Scholar
• Kozako T, Aikawa A, Shoji T, Fujimoto T, Yoshimitsu M, Shirasawa S, Tanaka H, Honda S, Shimeno H, Arima N, et al. High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. Int J Cancer 2012; 131:2044 - 55; http://dx.doi.org/10.1002/ijc.27481; PMID: 22322739
   PubMed Web of Science ®Google Scholar
• Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010; 2:a001222; http://dx.doi.org/10.1101/cshperspect.a001222; PMID: 20463003
   PubMed Web of Science ®Google Scholar
• Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 2004; 14:408 - 12; http://dx.doi.org/10.1016/j.tcb.2004.07.006; PMID: 15308206
   PubMed Web of Science ®Google Scholar
• Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120:2479 - 87; http://dx.doi.org/10.1242/jcs.001222; PMID: 17646672
   PubMed Web of Science ®Google Scholar
• Lam M, Carmichael AR, Griffiths HR. An aqueous extract of Fagonia cretica induces DNA damage, cell cycle arrest and apoptosis in breast cancer cells via FOXO3a and p53 expression. PLoS One 2012; 7:e40152; http://dx.doi.org/10.1371/journal.pone.0040152; PMID: 22761954
   PubMedGoogle Scholar
• Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008; 27:Suppl 1 S71 - 83; http://dx.doi.org/10.1038/onc.2009.45; PMID: 19641508
   PubMed Web of Science ®Google Scholar
• Hikisz P, Kiliańska ZM. PUMA, a critical mediator of cell death-one decade on from its discovery. Cell Mol Biol Lett 2012; 17:646 - 69; http://dx.doi.org/10.2478/s11658-012-0032-5; PMID: 23001513
   PubMed Web of Science ®Google Scholar
• Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29:684 - 8; http://dx.doi.org/10.1042/BST0290684; PMID: 11709054
   PubMed Web of Science ®Google Scholar
• Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. Br J Cancer 2008; 99:689 - 94; http://dx.doi.org/10.1038/sj.bjc.6604557; PMID: 18728657
   PubMed Web of Science ®Google Scholar
• Samimi S, Morrissey K, Anshelevich S, Evans K, Gardner J, Musiek A, Vittorio C, Rook A, Kim E. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma. J Am Acad Dermatol 2013; 68:e5 - 6; http://dx.doi.org/10.1016/j.jaad.2011.06.043; PMID: 23244387
   PubMed Web of Science ®Google Scholar
• Zhang X, Han S, Kang Y, Guo M, Hong S, Liu F, Fu S, Wang L, Wang QX. SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection. Cell Mol Immunol 2012; 9:390 - 8; http://dx.doi.org/10.1038/cmi.2012.28; PMID: 22922441
   PubMed Web of Science ®Google Scholar
• Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 2011; 508:185 - 91; http://dx.doi.org/10.1016/j.abb.2010.10.020; PMID: 21036138
   PubMed Web of Science ®Google Scholar
• Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle 2011; 10:1303 - 11; http://dx.doi.org/10.4161/cc.10.8.15353; PMID: 21436619
   PubMed Web of Science ®Google Scholar
• Schmit TL, Nihal M, Ndiaye M, Setaluri V, Spiegelman VS, Ahmad N. Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Res 2012; 72:3864 - 72; http://dx.doi.org/10.1158/0008-5472.CAN-12-0714; PMID: 22593191
   PubMed Web of Science ®Google Scholar